In addition to the description of the specific classification name of the tumor, the size of the tumor, whether the margins are cleanly removed, the site and number of lymph node metastasis, and whether there is any infiltration in the blood vessels and lymphatic vessels and other tissues in the postoperative pathology of breast cancer, there are also some important immune indexes that can indicate the prognosis, and by analyzing these indexes, the treatment can be guided and the prognosis can be estimated. The following are common immunologic indicators that may be found in hospital tests and their interpretation. ER: estrogen receptor, positive indicates a better prognosis than negative patients, the more plus signs the better. PR: progesterone receptor, positive suggests a better prognosis than negative patients. ER and PR are present in normal mammary epithelial cells and are partially and completely absent when the cells become cancerous. If the cells still retain ER and/or PR, the growth and proliferation of the breast cancer cells are still regulated by endocrine secretion, which is called hormone-dependent breast cancer; if ER and/or PR are missing, the growth and proliferation of the breast cancer cells are no longer regulated by endocrine secretion, which is called non-hormone-dependent breast cancer. A positive prognosis is best when both are positive, e.g., in a positive and a negative, estrogen positive is better than progesterone positive. Both negative have a poor prognosis. Those who are positive can be treated with endocrine therapy either postoperatively or preoperatively. Her-2 (CerbB-2): Human epidermal growth factor receptor 2, a proto-oncogene. Its overexpression, i.e., the presence of a plus sign, indicates that the patient has a poor prognosis. It also suggests that the patient is prone to axillary lymph node metastasis and may be deficient in both of these hormone receptors. It is lowly expressed in normal breast tissues, but its expression rate may increase in breast cancer tissues. Its expression is positively correlated with breast cancer grade, lymph node metastasis and clinical stage, and the higher the expression rate, the worse the prognosis may be. However, those with two plus signs or more on the Fish test have the potential for biologically targeted therapy. That is, with trastuzumab (Herceptin). All three of these are negative patients with what is now called “triple-negative” breast cancer, which has a relatively poor prognosis and lacks drug therapy. E-Cadherin: E-Cadherin is a transmembrane protein isoform of the calreticulin family of molecules, which is concentrated in the adherens junctions and plays an important role in the maintenance of epithelial cell integrity, polarity, morphology and organization. Its high expression indicates a favorable prognosis. Ki-67index: a proliferation antigen that responds to cell proliferation, its expression is associated with breast cancer occurrence and development and is a poor prognostic factor. The higher the value, the worse the prognosis. P53: it is a tumor suppressor gene, and its mutation indicates poor prognosis. breast cancer cells with high P53 mutation rate have high proliferative activity, poor differentiation, high malignancy, high invasiveness and high lymph node metastasis rate. CK5/6: CK5/6 is a cytokeratin protein, the higher the histological grade and the higher the tumor stage, the higher the expression rate, and in general, a positive prognosis is poor. EGFR: epidermal growth factor receptor, the higher the histological grade and the higher the tumor stage, the higher the expression rate, generally speaking, also positive suggests a poor clinical prognosis. VEGF: vascular endothelial growth factor, high expression suggests poor prognosis. TOP-II: DNA topoisomerase II, high expression suggests high tumor proliferation and malignancy.